BRAF V600E expression in ameloblastomas-A 36-patient cohort from Helsinki University Hospital.
Jetta KelppeHanna ThorénAri RistimäkiCaj HaglundTimo SorsaJaana HagströmPublished in: Oral diseases (2019)
An immunohistochemical BRAF marker could be a beneficial tool to predict the outcome of patients with this aggressive, easily recurring tumor.